South Korean aesthetic laser device specialist Laseroptek has unveiled the VASCURA 589, the world’s first solid-state laser to deliver a 589nm wavelength via KGW Raman architecture. The device targets vascular skin conditions and pigmentation treatments, promising lower maintenance costs and higher clinical efficiency. For overseas buyers and distributors, this signals a potential shift in the vascular laser segment, long dominated by expensive dye-based systems.
Technology breakthrough
VASCURA 589 uses a KGW Raman architecture to convert amplified 1064nm wavelength to 532nm, then stimulates KGW crystal to generate 589nm. This solid-state approach eliminates the need for costly dye kits, which are a recurring expense and environmental burden in traditional pulsed-dye lasers. The device outputs up to 10J with a quasi-long pulse structure (0.5–40ms), enabling stable energy delivery.
Clinical and operational advantages
The laser is designed for treating vascular lesions such as hemangiomas, port-wine stains, rosacea, and flushing, as well as pigmentation issues like melasma and skin toning. Its sub-pulse mode (10-nanosecond intervals) achieves therapeutic effects with 20–30% lower energy compared to other wavelengths, reducing patient pain and bruising. CEO Changjin Lee highlighted that annual maintenance costs are less than half of conventional equipment, as only the applicator needs replacement when changing spot size, not the entire handpiece. An auto-calibration function further enhances usability.
Regulatory and channel signals
VASCURA 589 received South Korea MFDS approval in February 2025, but the company delayed full launch to finalize clinical protocols and stabilize component supply amid global uncertainties. Laseroptek is now actively pursuing US FDA clearance, targeting approval by end of 2025 or Q1 2026. The company also plans to enter Brazil and other key markets. This phased regulatory strategy suggests a methodical approach to global distribution.
Market ambition and sourcing context
Laseroptek aims to replace over half of the domestic vascular laser market within three years, citing its earlier success with the UV laser device 'Pallas' that captured significant share from foreign competitors. The company expects VASCURA 589 to drive about 30% of total revenue, targeting KRW 100 billion in total sales. For overseas buyers, this device offers a solid-state alternative to dye lasers, with lower consumable costs and a clear regulatory pathway. Distributors should monitor FDA progress and evaluate compatibility with local clinical protocols.
Source: Read the original report | Published: June 15, 2026